CORRESP 1 filename1.htm

Jyong Biotech Ltd.

23F-3, No. 95, Section 1, Xintai 5th Road

Xizhi District, New Taipei City

Taiwan, 221

June 12, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Ms. Doris Stacey Gama/ Ms. Suzanne Hayes

	Re:	Jyong Biotech Ltd.
		Post-Effective Amendment No. 2 to Registration Statement on Form F-1
		File No. 333-277725

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Jyong Biotech Ltd. (the “Company”) respectfully requests that the effective date of the registration statement referred to above (the “Registration Statement”) be accelerated so that it will become effective at 4:00 p.m., Eastern Time, on Monday, June 16, 2025, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Sichenzia Ross Ference Carmel LLP by calling Shane Wu, Esq. at (202) 322-8852. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Sichenzia Ross Ference Carmel LLP, Attention: Shane Wu, Esq, by email at swu@srfc.law and Tomer Magid, by email at tmagid@srfc.law.

If you have any questions regarding this request, please contact Shane Wu, Esq. of Sichenzia Ross Ference Carmel LLP, at (202) 322-8852.

	Very Truly Yours,
	By:	/s/ Fu-Feng Kuo
	Name:	Fu-Feng Kuo
	Title:	Chief Executive Officer

cc: Shane Wu, Esq. of Sichenzia Ross Ference Carmel LLP